Ingredient in pre-clinical treatment for retinal neovascular disease targets gene associated with acute myeloid leukaemia
An active ingredient in eye drops that were being developed for the treatment of a form of eye disease has shown promise for treating an aggressive form of blood cancer. Scientists at the Wellcome Sanger Institute, University of Cambridge, University of Nottingham and their collaborators have found that this compound, which targets an essential cancer gene, could kill leukaemia cells without harming non-leukemic blood cells.
The results, published today (19 December) in Nature Communications reveal a potential new treatment approach for an aggressive blood cancer with a poor prognosis.
Acute myeloid leukaemia (AML) is a form of blood cancer that affects people of all ages, often requiring months of intensive chemotherapy and prolonged hospital admissions. It develops in cells in the bone marrow crowding out the healthy cells, in turn leading to life-threatening infections and bleeding.
Mainstream AML treatments have remained unchanged for over 30 years, with the current treatment being chemotherapy, and the majority of people’s cancer cannot be cured. A subtype of AML, driven by rearrangements in the MLL gene has a particularly bad prognosis.
In a previous study, researchers at the Sanger Institute developed an approach, based on CRISPR gene editing technology, which helped them identify more than 400 genes as possible therapeutic targets for different subtypes of AML. One of the genes, SRPK1, was found to be essential for the growth of MLL-rearranged AML. SRPK1 is involved in a process called RNA splicing, which prepares RNA for translation into proteins, the molecules that conduct the majority of normal cellular processes, including growth and proliferation.
In a new study, Sanger Institute researchers and their collaborators set out to work out how inhibition of SRPK1 can kill AML cells and whether it has therapeutic potential in this disease. They first showed that genetic disruption of SRPK1 stopped the growth of MLL-rearranged AML cells and then went on to study the compound SPHINX31, an inhibitor of SRPK1, which was being used to develop an eye drop treatment for retinal neovascular disease – the growth of new blood vessels on the retinal surface that bleed spontaneously and cause vision loss.
The team found that the compound strongly inhibited the growth of several MLL-rearranged AML cell lines, but did not inhibit the growth of normal blood stem cells. They then transplanted patient-derived human AML cells into immunocompromised mice and treated them with the compound. Strikingly, the growth of AML cells was strongly inhibited and the mice did not show any noticeable side effects.
“We have discovered that inhibiting a key gene with a compound being developed for an eye condition can stop the growth of an aggressive form of acute myeloid leukaemia without harming healthy cells. This shows promise as a potential approach for treating this aggressive leukaemia in humans.”
Dr George Vassiliou, joint leader of the research from the Wellcome Sanger Institute and the Wellcome-MRC Cambridge Stem Cell Institute
SRPK1 controls the splicing* of RNA in the production of new proteins. An example of a gene that is affected when SRPK1 is blocked is BRD4, a well-known gene that maintains AML. Inhibiting SRPK1 causes the main form of BRD4 to switch to another form, a change that is detrimental to AML growth.
“Our study describes a novel mechanism required for leukaemia cell survival and highlights the therapeutic potential of SRPK1 inhibition in an aggressive type of AML. Targeting this mechanism may be effective in other cancers where BRD4 and SRPK1 play a role, such as metastatic breast cancer.”
Dr Konstantinos Tzelepis, joint lead author from the Wellcome Sanger Institute and University of Cambridge
“When Dr Vassiliou told me that SRPK1 was required for the survival of a form of AML, I immediately wanted to work with him to find out if our inhibitors could actually stop the leukaemia cells growing. The fact that the compound worked so effectively bodes well for its potential development as a new therapy for leukaemia. It will take some time, but there is real promise for a new treatment on the horizon for patients with this aggressive cancer.”
Professor David Bates, from the University of Nottingham and co-founder of biotech company Exonate, which develops eye drops for retinal diseases
Learn more: From eye drops to potential leukaemia treatment
The Latest on: Acute myeloid leukaemia
via Google News
The Latest on: Acute myeloid leukaemia
- Blood donors help cancer patient beat the odds on February 18, 2019 at 10:24 pm
In Hand's case, it progressed quickly. Within days, she was told she'd developed acute myeloid leukemia or AML. "I was stunned, really, when I got the diagnosis," Hand remembers. "My husband was stunn... […]
- I am dying of Leukemia on February 18, 2019 at 5:05 pm
It is the most common type of leukemia overall, and occurs about twice as often in men as in women. 3. Acute myeloid leukemia (AML) causes uncontrolled production of another type of white blood cell c... […]
- Mum, 35, who blamed cough and weight loss on stress discovers it’s actually sign of leukaemia on February 18, 2019 at 2:38 am
Leukaemia is a type of blood cancer that attacks the immune system. The disease is often classified as the type of cell affected (myeloid or lymphatic) and how it progresses (acute or chronic). Often, ... […]
- New Approach to Treat Leukemia Discovered on February 18, 2019 at 2:17 am
Acute myeloid leukemia (AML), the most common form of acute leukemia, is characterized by an increase of malignant myeloid progenitor cells at the expense of mature blood cells. Only twenty-five perce... […]
- Mother, 35, discovers her cough that wouldn't shift is life-threatening LEUKAEMIA on February 17, 2019 at 6:59 pm
From this she was diagnosed with acute myeloid leukaemia, a cancer of the white blood cells, and admitted to Newcastle's Freeman Hospital for six weeks. 'To be told I couldn't go home and that I neede... […]
- Vor Biopharma raises $42m to advance development of cell therapy product candidate for AML on February 15, 2019 at 2:52 am
Vor plans to use the proceeds from the financing to advance its lead HSC-based candidate for the treatment of acute myeloid leukemia (AML) towards the clinic, and to further build its pipeline to trea... […]
- 29-Year-Old's Leukemia Fight Highlights Hurdles Certain Ethnicities Face In Finding Bone Marrow Match on February 14, 2019 at 6:35 am
The search is on for a bone marrow transplant for a 29-year-old journalist from Orange County, California, who is in the hospital with acute myeloid leukemia, an aggressive form of the cancer. Liyna A... […]
- Novel AML Strategies Aim to Restore Regulatory Gene Functions on February 13, 2019 at 1:09 pm
The disseminated malignancy with the best overall survival today is acute promyelocytic leukemia (APL), a rare genetic subtype of de novo acute myeloid leukemia (AML), which accounts for less than 10% ... […]
- New Study to Focus on Unique Needs of Acute Myeloid Leukemia Patients on February 11, 2019 at 9:44 am
WASHINGTON: The Cancer Support Community (CSC), a global nonprofit, is launching a unique research study focused on individuals diagnosed with Acute Myeloid Leukemia (AML), a cancer of the blood and b... […]
- Does Chemotherapy Increase the Risks of Myelodysplastic Syndrome and Acute Myeloid Leukemia? on February 7, 2019 at 8:58 am
Receipt of chemotherapy was associated with a 1.5-fold to more than 10-fold higher risk of developing therapy-related myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) for 22 types of sol... […]
via Bing News